Reversal of multidrug resistance by the Chinese medicine Yiqi Jianpi Huaji decoction and the mechanism of action in human gastric cancer SGC7901/VCR cells

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Li, Wei Bing ^a   Li, Yang ^b   Yu, Chen ^a   He, Yong Ming ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHINESE DRUG; CHOLECYSTOKININ OCTAPEPTIDE; FLUOROURACIL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PLANT EXTRACT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; YIQI JIANPI HUAJI DECOCTION;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CHINESE MEDICINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SYNTHESIS; FLOW CYTOMETRY; GASTRIC CANCER CELL LINE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; STOMACH CANCER; WESTERN BLOTTING;

EID: 84923879614     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/390812     Document Type: Article

References (24)

1. J. Ferlay, H. R. Shin, F. Bray et al., GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 10 Lyon, France, International Agency for Research on Cancer, Lyon, France, 2010.
2. X. Sun, R. Mu, Y. Zhou et al., "1990-1992 mortality of stomach cancer in China," Chinese Journal of Oncology, vol. 24, no. 1, pp. 4-8, 2002.
3. S. Labialle, L. Gayet, E. Marthinet, D. Rigal, and L. G. Baggetto, "Transcriptional regulators of the humanmultidrug resistance 1 gene: recent views," Biochemical Pharmacology, vol. 64, no. 5-6, pp. 943-948, 2002.
4. C. Mignogna, S. Staibano, V. Altieri et al., "Prognostic significance of multidrug-resistance protein (MDR-1) in renal cancer cell carcinomas: a five year follow-up analysis," BMC Cancer, vol. 6, article 293, 2006.
5. X.-Q. Yu, C. C. Xue, G. Wang, and S.-F. Zhou, "Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs," Current Drug Metabolism, vol. 8, no. 8, pp. 787-802, 2007.
6. E. K. Fetisova, A. V. Avetisyan, D. S. Izyumov, M. V. Korotetskaya, B. V. Chernyak, and V. P. Skulachev, "Mitochondriatargeted antioxidant SkQR1 selectively protectsMDR(Pgp 170)- negative cells against oxidative stress," FEBS Letters, vol. 584, no. 3, pp. 562-566, 2010.
7. G. Nardone, A. Rocco, D. Vaira et al., "Expression of COX-2, mPGE-synthase1,MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis," The Journal of Pathology, vol. 202, no. 3, pp. 305-312, 2004.
8. Y. Zhang, X. Qu, X. Hu et al., "Reversal of P-glycoproteinmediated multi-drug resistance by the E3 ubiquitin ligase Cblb in human gastric adenocarcinoma cells," The Journal of Pathology, vol. 218, no. 2, pp. 248-255, 2009.
9. H.-W. Xu, L. Xu, J.-H. Hao, C.-Y. Qin, and H. Liu, "Expressionof P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer," The Journal of International Medical Research, vol. 38, no. 1, pp. 34-42, 2010.
10. W. Liu, Y.-H. Yu, X.-N. Ouyang et al., "Clinical significance of Pglycoprotein and topoisomerase II expression in gastric cancer," The World Chinese Journal of Digestology, vol. 18, no. 34, pp. 3640-3647, 2010.
11. V. Vallacchi,M. Daniotti, F. Ratti et al., "CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma," Cancer Research, vol. 68, no. 3, pp. 715-723, 2008.
12. M. Cervello and G. Montalto, "Cyclooxygenases in hepatocellular carcinoma,"World Journal of Gastroenterology, vol. 12, no. 32, pp. 5113-5121, 2006.
13. L. Yang and D. D. Wei, "Reversal effects of traditional Chinese herbs on multidrug resistance in cancer cells," Phytotherapy Research, vol. 26, no. 4, pp. 562-567, 2012.
14. L. Yang, D. D. Wei, Z. Chen, J. S. Wang, and L.Y. Kong, "Reversal of multidrug resistance in human breast cancer cells by Curcuma wenyujin and Chrysanthemum indicum," Phytomedicine, vol. 18, no. 8-9, pp. 710-718, 2011.
15. G. Gu, I. Barone, L. Gelsomino et al., "Oldenlandia diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERα/Sp1-mediated p53 activation," Journal of Cellular Physiology, vol. 227, no. 10, pp. 3363-3372, 2012.
16. J. Sun, S. Wang, and Y.-H. Wei, "Reproductive toxicity of Rhizoma Sparganii (Sparganium stoloniferum Buch.-Ham.) in mice: mechanisms of anti-angiogenesis and anti-estrogen pharmacologic activities," Journal of Ethnopharmacology, vol. 137, no. 3, pp. 1498-1503, 2011.
17. D. M. Dykxhoorn, D. Palliser, and J. Lieberman, "The silent treatment: SiRNAs as smallmolecule drugs," GeneTherapy, vol. 13, no. 6, pp. 541-552, 2006.
18. P. B. Mullan, J. E. Quinn, P. M. Gilmore et al., "BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents," Oncogene, vol. 20, no. 43, pp. 6123-6131, 2001.
19. S. Peng and G. Ting-Jie, "Jian Pi YangWei compound on human gastric cancer cell line SGC7901 experiment on growth inhibition and apoptosis," Jiangsu Journal of Traditional Chinese Medicine, vol. 45, no. 3, pp. 70-72, 2013.
20. P. Seve, S. Isaac, O. Trédan et al., "Expression of class iii β- tubulin is predictive of patient outcome in patients with non- small cell lung cancer receiving vinorelbine-based chemotherapy," Clinical Cancer Research, vol. 11, no. 15, pp. 5481-5486, 2005.
21. Y. Zhang, H. Yang, J. Liu et al., "High expression levels of class IIIbeta-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbinebased adjuvant chemotherapy," Oncology Letters, vol. 6, no. 1, pp. 220-226, 2013.
22. E. Alli, J.-M. Yang, J. M. Ford, and W. N. Hait, "Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells,"Molecular Pharmacology, vol. 71, no. 5, pp. 1233-1240, 2007.
23. C. Aschele, S. Lonardi, and S. Monfardini, "Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine- based chemotherapy in advanced colorectal cancer," Cancer Treatment Reviews, vol. 28, no. 1, pp. 27-47, 2002.
24. S. Popat, A. Matakidou, and R. S. Houlston, "Thymidylatesynthase expression and prognosis in colorectal cancer: a systematic review andmeta-analysis," Journal of Clinical Oncology, vol. 22, no. 3, pp. 529-536, 2004.